Cibus (CBUS) Fundamentals 2026 — Revenue Analysis | SniperIQ
Cibus (CBUS) is a US-listed Healthcare company in Biotechnology with a market capitalization of $80M, trading at
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Cibus's market cap?
Cibus (CBUS) has a market capitalization of approximately $80M, trading at
What is Cibus's P/E ratio?
Cibus's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 32.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Cibus?
Cibus runs a net profit margin of -2366.3%, a gross margin of 72.1%, and an operating margin of -1375.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Cibus generate?
Cibus reported revenue of $4M for fiscal year 2025, with net income of -
Does Cibus pay a dividend?
Cibus does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Cibus financially healthy?
Cibus carries a debt-to-equity ratio of 7.78x and a current ratio of 2.37x, with a market beta of 1.65. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Cibus a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Cibus (CBUS) the key facts are: market cap $80M, revenue $4M, 52-week range 1.09-4.191. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Cibus's full fundamentals live
Get Cibus's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.